Serum S100B In Patients Research Articles

The expression of S100B protein in serum of patients with brain metastases from small-cell lung cancer and its clinical significance.

The objective of the present study was to investigate the expression of S100B protein in serum of patients with brain metastases from small cell lung cancer (SCLC), and its clinical significance. A total of 138 patients with SCLC were selected from June 2013 to December 2015. Simultaneously, 138 healthy adult volunteers (healthy controls) were selected in the medical examination center of People's Hospital of Rizhao. Among the 138 patients with SCLC, 48 had liver metastases and 44 had brain metastases. Of the remaining 46 patients, 20 were initially diagnosed with SCLC and 26 underwent surgery and postoperative chemotherapy. The levels of serum S100B in patients and healthy controls were measured by ELISA, and analyzed by SPSS 20.0 statistical software. The serum S100B protein levels in patients with SCLC were significantly higher than those in healthy controls (p<0.05). Among the subgroups of patients with SCLC, the levels of serum S100B in patients with brain metastases were significantly higher than in the other subgroups (p<0.05). No significant differences were found between the other subgroups, except for the brain metastases group. We found that serum S100B protein expression levels were significantly reduced in patients with brain metastases after cobalt-60 radiotherapy (p<0.05). During follow-up, we found that higher expression of S100B protein was usually associated with poorer prognosis, higher mortality rate at 1 year, and lower survival rate. In conclusion, S100B protein can serve as a serological marker for brain metastases from SCLC, which provides important theoretical support for early detection of brain metastases.

Serum S100B in manic bipolar disorder patients: Systematic review and meta-analysis

BackgroundBipolar disorder (BD) is a neuropsychiatric disorder characterized by recurrent episodes of mania/hypomania, affecting more than 1% of the world population. S100B is a calcium-binding protein, mostly produced and secreted by astrocytes in the CNS that participate in several cellular responses. Previous studies have shown that patients with bipolar disorder had higher peripheral S100B levels than healthy individuals, suggesting a potential role for S100B BD. MethodsIn this study, a systematic and quantitative meta-analysis of studies S100B serum was performed according to the guidelines PRISMA-statement to confirm the increase of serum S100B in patients with manic bipolar disorder. ResultsWe included in the meta-analysis two studies that reported the mean and standard deviation of serum S100B 52 patients manic BP and 52 control studies. Our results showed higher levels of S100B peripheral TB patients compared with healthy controls. In this meta-analysis, we found evidence that serum S100B are increased in patients with bipolar disorder. ConclusionIn conclusion, several studies have observed morphological abnormalities in the brains of bipolar disorder patients, changes in the peripheral S100B levels in mood disorders were described, and this protein could be a putative marker for damage to the brain. Thus, in this meta-analysis we have found evidence, based on two studies of 52 patients and 52 healthy controls, that the serum concentrations of S100B are increased in bipolar disorder patients.

Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma.

Serum lactate dehydrogenase is a more useful biomarker of prognosis than serum S100B in patients with BRAF-mutant melanoma.

Serum S100B in patients with brain tumours undergoing craniotomy.

To determine pre- and postoperative serum S100B concentrations in patients with intracranial tumours that underwent craniotomy and compare the values with healthy controls. An observational, comparative study. Neurosurgical Ward, Jinnah Postgraduate Medical Centre. Karachi, from May 2007 to April 2008. Serum S100B was measured pre- and postoperatively on days 1, 2 and 7 in 18 healthy controls and similar number of patients who underwent craniotomy for intracranial tumours. Mean pre-operative patients and control values were compared using Mann-Whitney (unpaired) or Wilcoxon (paired) tests for comparing between pre- and postoperative values. The p-value was considered significant at < 0.05. Serum S100B concentrations were significantly higher in patients with mean value of 0.19 ± 0.12 μg/L than in healthy controls (mean 0.03 ± 0.01, p < 0.0005). Significantly raised serum S100B concentrations were observed in all postoperative samples when compared with pre-operative samples. S100B concentrations significantly increased on postoperative day 1 (mean = 0.90 ± 1.07 μg/L, p < 0.0005), decreased on day 2 (mean = 0.84 ± 0.57 μg/L, p < 0.0005). The concentrations further declined on day 7 (mean = 0.44 ± 0.43 μg/L, p = 0.005). The significantly high postoperative concentrations of S100B in patients appear as a consequence of tissue damage due to surgical procedures. The absence of fall of the S100B concentration in serum from the peak value on postoperative day 1 and day 2 could provide early warning of brain tissue damage leading to neurological deterioration.

Serum S100B in patients with and without delirium

Serum S100B in patients with and without delirium

Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694

We evaluated adjuvant trial E1694 to more precisely define the prognostic significance of serum S100B in patients with high-risk resected melanoma. Sera from 670 E1694 patients banked at baseline and three additional time points were tested for S100B protein using chemiluminescence. S100B testing results showed that the higher the S100B level is, the higher the risk of relapse and death, regardless of the cutoff value. Univariate analysis showed that baseline S100B > or = 0.15 microg/L is significantly correlated with overall survival (OS; P = .01). Multivariate analysis was performed adjusting for significant prognostic factors (ulceration and lymph node status) and treatment. Baseline S100B was a significant prognostic factor for survival (hazard ratio = 1.39; 95% CI, 1.01 to 1.92; P = .043). S100B values measured at later time points over 1 year were also demonstrated to be significant prognostic factors for relapse-free survival (RFS) and OS. Lower S100B values at baseline and during follow-up were associated with longer survival. A changing S100B from low at baseline to high on follow-up seemed to be associated with the worst RFS and OS. For patients with high-risk surgically resected melanoma, a high baseline or increasing serum S100B is an independent prognostic marker of risk for mortality that may allow us to refine the application of adjuvant therapy in the future.

The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis

S100B protein detected in the serum of patients with cutaneous melanoma has been long reported as a prognostic biomarker. However, no consensus exists on its implementation in the routine clinical setting. This study aimed to comprehensively and quantitatively summarize the evidence on the suitability of serum S100B to predict patients' survival. Twenty-two series enrolling 3393 patients with TNM stage I to IV cutaneous melanoma were reviewed. Standard meta-analysis methods were applied to evaluate the overall relationship between S100B serum levels and patients' survival (meta-risk). Serum S100B positivity was associated with significantly poorer survival (hazard ratio [HR] = 2.23, 95% CI: 1.92-2.58, p < 0.0001). Between-study heterogeneity was significant, which appeared to be related mainly to dissemination bias and the inclusion of patients with stage IV disease. Considering stage I to III melanoma (n = 1594), the meta-risk remained highly significant (HR = 2.28, 95% CI: 1.8-2.89; p < 0.0001) and studies' estimates were homogeneous. Subgroup analysis of series reporting multivariate survival analysis supported S100B as a prognostic factor independent of the TNM staging system. Our findings suggest that serum S100B detection has a clinically valuable independent prognostic value in patients with melanoma, with particular regard to stage I-III disease. Further investigation focusing on this subset of patients is justified and warranted before S100B can be implemented in the routine clinical management of melanoma.

Lack of Elevation of Serum S100B in Patients with Metastatic Melanoma as a Predictor of Outcome After Induction with an Autologous Vaccine of Proliferating Tumor Cells and Dendritic Cells

Serum levels of S100B and/or lactate dehydrogenase (LDH) are putative tumor markers in melanoma. Early changes in such markers may correlate with a positive immune response to vaccine therapy. In patients with metastatic melanoma, S100B and LDH serum levels were measured at baseline, and 1 week after 3 weekly subcutaneous injections of investigational, patient-specific vaccines consisting of autologous dendritic cells loaded with antigens from irradiated proliferating autologous tumor cells, and suspended in granulocyte macrophage colony-stimulating factor. There was a poor correlation between S100B and LDH levels at baseline (p = 0.324). Fourteen (14) patients with measurable disease had higher S100B (p = 0.0456) and LDH (p = 0.0013) levels than 31 patients who lacked measurable disease at that time. Fourteen (14) deceased patients (median survival, 13 months) had a mean baseline S100B of 0.62 mug/L (95% confidence interval [CI] 0.00-1.66) and LDH of 815 U/L (95% CI 222-1408); 31 surviving patients (median follow-up, 35.4 months) had mean S100B of 0.07 mug/L (95% CI 0.00-0.23; p = 0.006) and LDH of 442 U/L (95% CI 296-588; p = 0.002). Elevated baseline levels of LDH and S100B were each predictive of inferior progression-free survival (PFS) and overall survival (OS) (both p < 0.0001), but S100B was a better predictor for PFS than LDH. Changes in LDH between baseline and week 4 were not predictive of survival, but an increase in S100B predicted for inferior OS ( p = 0.039). Both LDH and S100B are predictive tumor markers in patients with metastatic melanoma. This is the first study to examine the changes in serum levels of LDH and S100B in response to an autologous tumor-cell vaccine.